Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donita Dyalram

Oral & Maxillofacial Surgery Baltimore, MD Medical Doctor

NPI 1013107572 CMS profile 1047051

650 W Baltimore St, Suite 1401, Baltimore, MD 21201

Open in the dashboard

General payments

$112,079

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donita Dyalram of Baltimore, MD is reported in the CMS Open Payments database as having received $112,079 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Oral & Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,742 36
2024 General $4,521 21
2023 General $30,674 28
2022 General $15,901 31
2021 General $6,360 15
2020 General $1,919 2
2019 General $6,963 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donita Dyalram
  • Oral & Maxillofacial Surgery median
  • Middle half of Oral & Maxillofacial Surgery
  • National median

In program year 2025, general payments to Donita Dyalram were reported at $45,742. Among 792 Oral & Maxillofacial Surgery profiles paid that year, the median was $184 and the middle half received between $61 and $541.

Show as a table
Year Donita Dyalram Oral & Maxillofacial Surgery median Middle half National median
2019 $6,963 $178 $56–$584 $163
2020 $1,919 $106 $38–$316 $114
2021 $6,360 $165 $57–$511 $132
2022 $15,901 $173 $63–$494 $149
2023 $30,674 $184 $62–$521 $160
2024 $4,521 $197 $65–$603 $164
2025 $45,742 $184 $61–$541 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $102,963 112 payments
  2. AxoGen $8,348 22 payments
  3. KLS-Martin L.P. $669 9 payments
  4. 3D Systems $57 1 payment
  5. Baxter Healthcare $42 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $84,113 16 payments
  2. Travel and Lodging $16,736 53 payments
  3. Food and Beverage $5,568 75 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,600 1 payment
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,063 1 payment
Products named General payments · program years 2019–2025
  1. VSP SYSTEM, VSP CRANIAL $76,785 40 payments
  2. NA Craniomaxillofacial $43,733 41 payments
  3. NA Craniomaxillofacial $28,785 46 payments
  4. MEDPOR TITAN $8,400 1 payment
  5. AXOGUARD NERVE PROTECTOR $7,864 12 payments
  6. AxoGuard Nerve Connector $7,864 12 payments
  7. PATIENT-FITTED TMJ RECONSTRUCTIVE PROSTHESIS SYSTEM $7,638 1 payment
  8. NA Craniomaxillofacial $6,339 8 payments
  9. UNIVERSAL NEURO 2 $5,225 1 payment
  10. NA Neuro $2,341 11 payments
  11. Other $5,599 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

24

Median for Maxillofacial Surgery: 343

Drug cost

$449

Median for Maxillofacial Surgery: $1,437

Branded share of claims

0%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Triamcinolone Acetonide Generic 11 $338
Oxycodone Hcl Generic 13 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$91,478

Medicare's payments for the services billed

Medicare patients

171

Average age 75

Services billed

446

103 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 40%
Diabetes 26%
Cancer 22%
Depression 22%
Ischemic heart disease 20%
Chronic kidney disease 16%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Oral & Maxillofacial Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record